Effects of inhibitors of the renin‐angiotensin system on reducing blood pressure and expression of inflammatory factors in CHD patients: A network meta‐analysis.

The renin‐angiotensin system (RAS) is an ever‐evolving endocrine system with considerable checks and balances on the production and catabolism of angiotensin peptides most likely due to the manifold effects of angiotensins. We aimed to explore the effects of different inhibitors of RAS on blood pressure and expression of inflammatory factors in patients with coronary heart disease (CHD). We initially searched PubMed, EMBASE and Cochrane Library electronic databases with nine eligible randomized controlled trials enrolled. Direct and indirect evidence was combined to calculate the weighted mean difference value and draw surface under the cumulative ranking curves. The results demonstrated that, compared with placebo and enalapril, ramipril had a better effect on reducing systolic blood pressure after short‐term usage of drugs (<12 months), while perindopril had better effects on reducing diastolic blood pressure and C‐reactive protein expression. Furthermore, after long‐term usage of drugs (≥12 months), there was no significant difference among olmesartan, quinapril and candesartan in the treatment of patients with CHD. Perindopril and ramipril had better effects on inhibiting blood pressure and expression of inflammatory factors among eight inhibitors after short‐term usage of drugs (<12 months); while quinapril had better effects on reducing blood pressure and expression of inflammatory factor after long‐term usage of drugs, and there was little difference in the effects between olmesartan and candesartan (≥12 months). Perindopril may have better short‐term effects on reducing blood pressure and expression of inflammatory factor, while quinapril may have better long‐term effects on reducing blood pressure and expression of inflammatory factor. Perindopril may have better short‐term effects on reducing blood pressure and expression of inflammatory factor, while quinapril may have better long‐term effects on reducing blood pressure and expression of inflammatory factor. [ABSTRACT FROM AUTHOR]